To create the tissues, Organovo reworks DNA, RNA and human cells to generate the 3D-printed tissues, according to CEO Taylor Crouch. The tissues can be used to repair damaged organs or improve function to help prolong their lifespan and reduce the need for transplants.
“It’s about personalized and customized treatment,” Xuanhe Zhao, PhD, professor of mechanical engineering at MIT, told The Boston Herald. “You wouldn’t even need the donors, you use your own cells to regenerate the tissue or organ you need.”
Organovo is in the process of testing 3D-printed human liver tissue in mice, but the company faces limitations in manufacturing and clinical trials.
Mr. Crouch said Organovo hopes to show the 3D-printed tissue technology will provide a cost benefit when compared to the cost of an organ transplant.
More articles on clinical leadership and infection control:
60% of Congo’s Ebola cases in October involved children, WHO says
FTC fines 2 stem cell centers $3.3M for advertising unproven treatments
First pediatric flu death reported in 2018-19 season
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.